Who
Steven Keith Burke
Director
Company insider
Files Form 4 as: Director, Scynexis; SVP, Chief Medical Officer, Akebia Therapeutics; SVP and Chief Medical Officer, Protara Therapeutics.
In numbers
- Trades disclosed
- 81
- Buys
- 2
- Sells
- 16
- Bought
- $119K
- Sold
- $555K
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 7 Jan 2015
- Last trade
- 18 Sep 2026
- Last filed
- 22 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Sep 2026filed 22 Sep 2026 | SCYX ScynexisBiotechnology | SEC FORM 4 Code A | —5,750 at $0.00 | filing |
| 18 Sep 2026filed 22 Sep 2026 | SCYX Scynexisoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,750 at $0.00 | filing |
| 18 Sep 2026filed 22 Sep 2026 | SCYX Scynexisoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,750 at $0.00 | filing |
| 18 Sep 2026filed 22 Sep 2026 | SCYX ScynexisBiotechnology | SEC FORM 4 Code A | —5,750 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $30K21,582 at $1.39 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $35K25,375 at $1.39 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $29K20,701 at $1.39 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $30K21,582 at $1.39 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $35K25,375 at $1.39 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $29K20,701 at $1.39 | filing |
| 30 Jan 2026filed 3 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —204,000 at $0.00 | filing |
| 30 Jan 2026filed 3 Feb 2026 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —320,000 at $0.00 | filing |
| 30 Jan 2026filed 3 Feb 2026 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —320,000 at $0.00 | filing |
| 30 Jan 2026filed 3 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —204,000 at $0.00 | filing |
| 3 Mar 2025filed 4 Mar 2025 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $13K7,144 at $1.83 | filing |
| 3 Feb 2025filed 4 Feb 2025 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $49K23,270 at $2.10 | filing |
| 3 Feb 2025filed 4 Feb 2025 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $57K27,236 at $2.10 | filing |
| 31 Jan 2025filed 4 Feb 2025 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —292,300 at $0.00 | filing |
| 31 Jan 2025filed 4 Feb 2025 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —194,900 at $0.00 | filing |
| 29 Feb 2024filed 1 Mar 2024 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $11K7,169 at $1.58 | filing |
News
Analyzing Akebia Therapeutics (NASDAQ:AKBA) and Pharming Group (NASDAQ:PHAR)AKBA · tickerreport.com · 18 Oct 2026Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health ForumAKBA · manilatimes.net · 7 Oct 2026
0 headlines in the last 90 days name Steven Keith Burke; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.